Chengming Fei
Impact in
- Hematology top 5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Iron Metabolism and Disorders
- Genetics top 10%
- Mesenchymal stem cell research
- Hemoglobinopathies and Related Disorders
Papers in
- Hematology 19
- Acute Myeloid Leukemia Research 16
- Iron Metabolism and Disorders 3
- Genetics 9
- Mesenchymal stem cell research 5
- Hemoglobinopathies and Related Disorders 4
Chengming Fei
23 papers receiving 488 citations
Peers
Comparison fields: 5 of 63
- Hematology 230
- Genetics 142
- Cancer Research 82
- Immunology 72
- Molecular Biology 234
Countries citing papers authored by Chengming Fei
This map shows the geographic impact of Chengming Fei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengming Fei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengming Fei more than expected).
Fields of papers citing papers by Chengming Fei
This network shows the impact of papers produced by Chengming Fei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengming Fei. The network helps show where Chengming Fei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chengming Fei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 12 | |
| 2 | 2019 | 51 | |
| 3 | 2018 | 93 | |
| 4 | 2018 | 7 | |
| 5 | 2018 | 33 | |
| 6 | 2017 | 3 | |
| 7 | 2017 | 13 | |
| 8 | 2017 | 35 | |
| 9 | 2017 | 14 | |
| 10 | 2016 | 11 | |
| 11 | Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. | 2016 | 58 |
| 12 | 2015 | 4 | |
| 13 | 2015 | 23 | |
| 14 | 2015 | 3 | |
| 15 | 2014 | 22 | |
| 16 | 2014 | 17 | |
| 17 | 2013 | 14 | |
| 18 | 2013 | 0 | |
| 19 | 2013 | 8 | |
| 20 | 2012 | 9 |
About Chengming Fei
Chengming Fei is a scholar working on Hematology, Genetics, Orthopedics and Sports Medicine, Cancer Research and Molecular Biology, having authored 25 papers that have together received 495 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (16 papers), Histone Deacetylase Inhibitors Research (6 papers), Mesenchymal stem cell research (5 papers), Hemoglobinopathies and Related Disorders (4 papers), MicroRNA in disease regulation (3 papers), Iron Metabolism and Disorders (3 papers), Bone and Joint Diseases (3 papers) and Bone health and treatments (2 papers). The work is most often cited by research in Hematology (230 citations), Genetics (142 citations), Cancer Research (82 citations), Immunology (72 citations) and Molecular Biology (234 citations). Chengming Fei has collaborated with scholars based in China. Frequent co-authors include Juan Guo, Youshan Zhao, Chunkang Chang, Sida Zhao, Dong Wu, Lingyun Wu, Li Xiao, Qingqing Zheng, Chao Xiao and Xiao Li. Their work appears in journals such as Tumor Biology, Blood, Scientific Reports, Cell Death and Disease and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.